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ABSTRACT 
BACKGROUND 
Schwann cells (SC) may play an important role in perineural invasion (PNI) by promoting 
cancer cell dispersion. Brain‐derived neurotrophic factor (BDNF) may contribute to these 
cellular events by activating tropomyosine receptor kinase B (TrkB). This study examines 
the effect of TrkB inhibition on SC migration and oral cancer cell dispersion in vitro. 
METHODS 
Human tongue squamous cell carcinoma (SCC‐9) and human SCs were cocultured in 
three different conditioned mediums: control, BDNF, and TrkB inhibitor. Cell migration, 
cancer cell dispersion, and SC dedifferentiation were measured on time‐lapse and 
immunofluorescence images. 
RESULTS 
Cancer cell migration exceeded SC migration in all conditions. TrkB inhibition promoted 
SC dedifferentiation and significantly increased SC migration, when compared to BDNF 
conditions. TrkB inhibition also reduced cancer cell dispersion, when compared to control 
and BDNF‐treated cultures. 
CONCLUSION 
SCs may have importance in the pathophysiology of PNI. TrkB inhibition may be a 
potential avenue for therapeutic intervention. 
 
 
 
 
 
 
 
 
1. INTRODUCTION 
Head and neck cancers (HNC) account for 3% of all new diagnosis of cancers and 1.8% 
of all deaths related to cancer in the United States. Up to 95% of all HNC diagnosed are 
squamous cell carcinoma (SCC).1 A significant prognostic factor of HNC is perineural 
invasion (PNI). In head and neck squamous cell carcinoma (HNSCC), PNI is associated 
with a decreased rate of overall survival (23% with PNI vs 49% without PNI), increased 
rate of local recurrence (23% with PNI vs 9% without PNI), and increased disease‐specific 
mortality (54% with PNI vs 25% without PNI).2, 3 This pathological feature is seen in up 
to 80% of cases.4 The conventional route of metastasis, including lymphotropic and 
vasculotrophic, are well understood biochemically.5 However, the molecular mechanisms 
of PNI remain an enigma. 
PNI occurs when tumor invades around, along, and throughout different layers of named 
and unnamed nerves.6 In the classical theory of PNI, cancer was thought to invade 
nerves via the path of least resistance in the perineural space. However, the nerve sheath 
is actually composed of multiple layers of collagen and basement membrane, which 
makes this path highly resistant. PNI is likely due to more complex mechanisms of 
invasion rather than simple diffusion of cancer cells.7 According to newer theories, PNI 
involves reciprocal signaling interactions between tumor cells and nerves, where nerves 
release trophic factors that stimulate cancer cells and cancer cells release neurotrophic 
factors that stimulate nerve infiltration. HNSCC has been shown to secrete factors that 
lead to neurite outgrowth, including nerve growth factor (NGF), brain derived growth factor 
(BDNF), and neurotrophin‐3 (NT‐3). The interactions of these neurotrophins with their 
high affinity receptors, tropomyosine receptor kinase (Trk) A, TrkB, and TrkC, 
respectively, is a new area of interest in the development of pharmaceutical therapies for 
many types of cancers.8 In particular, the BDNF/TrkB pathway is overexpressed in 
HNSCCs and found to be associated with aggressive behavior, poor prognosis, and 
resistance to chemotherapy. 
Schwann cells (SC) have been found to be closely associated with cancer cells in PNI 
specimens in colon cancer, thyroid cancer, salivary duct carcinomas, and skin squamous 
cell carcinomas.9-11 There is increasing evidence that SC play a major role in the tumor 
 
 
microenvironment, secreting neurotrophic factors and expressing high levels of Trk 
receptors.8, 12-16 Furthermore, cocultures of SC with salivary adenoid cystic carcinoma 
cells found increased BDNF secretion and TrkB expression, leading to epithelial‐to‐
mesenchymal transition (EMT) and mediation of the PNI process.17 Studies demonstrate 
that SC exhibit early and targeted migration toward human pancreatic cancer cells, 
preceding any cancer cell migration toward neurons in three‐dimensional in vitro 
experiments.10 Deborde et al9 elucidated that dedifferentiated SC direct pancreatic 
cancer cell migration toward nerve in a neural cell adhesion molecule 1 (NCAM‐1)‐
dependent mechanism, leading to cancer invasion following direct cancer cell contact.9 
These studies suggest that SC are activated in response to cancer cells, leading to a SC‐
cancer cell interaction that induces cancer cell propagation and is worthy of further 
investigation. 
The focus of this experiment was to analyze the communication between SC and cancer 
through BDNF activation of TrkB‐receptor and how this may contribute to the cellular 
events in HNSCC. A novel TrkB inhibitor, ANA‐12, was used to study the potential effects 
of downregulating the BDNF pathway and the in vitro implications for PNI (Figure 1). 
Figure 1. 
  
Communication between cancer and Schwann cells. An illustrative diagram 
demonstrating a potential mechanism of communication between head and neck 
 
 
squamous cell carcinoma and Schwann cells. Both cell types secrete brain‐derived 
neurotrophic factor (BDNF) that activate tropomyosin kinase B (TrkB) receptor. ANA‐12 
is a drug that can potentially block communications between cell types through inhibition 
of the TrkB receptor. 
2. MATERIALS AND METHODS 
2.1 CELL LINES AND CULTURE 
Primary human tongue squamous cell carcinoma (SCC9; CRL‐1629) cell line was 
purchased from the American Type Culture Collection (ATCC) and cultured according to 
the manufacturer's protocol. In brief, these cancer cells were cultured in uncoated flasks 
with maintenance media, consisting of 10% heat inactivated fetal bovine serum (FBS, 
Seradigm) and 90% mixture of Dulbecco's modified Eagle's medium (DMEM) and Ham's 
F12 medium (1:1) containing 1.2 g/L sodium bicarbonate, 2.5 mM L‐glutamine, 15 mM 
HEPES, 0.5 mM sodium pyruvate, and 400 ng/mL hydrocortisone at 37°C, 5% CO2. 
Primary human SC from normal peripheral nerve were obtained, purified, and cultured 
according to the methods reported by Monje.18 Briefly, the SC were plated on 0.01% 
poly‐L‐ornithine (Sigma Aldrich) and laminin (5 μg/mL; ThermoFisher) coated culture 
flasks in mitogenic media, consisting of DMEM (Sigma Aldrich), 10% FBS (Seradigm), 
Forskolin (2 μM; Sigma Aldrich), Heregulin (10 nM; Sigma Aldrich) and 1% penicillin‐
streptomycin (Gibco). All cells were grown at 37°C in a 5% CO2 incubator. Both cell lines 
were authenticated with immunofluorescence using primary antibodies against pan‐
cytokeratin (1:100, Novusbio, NBP2‐29429, Littleton CO), involucrin (1:100, Abcam, SY5, 
ab68, Cambridge, MA), S100 (1:100, Abcam, Ab868, Cambridge, MA), and Glial fibrillary 
acidic protein (GFAP; 1:250, Dako, Z0334, Santa Clara, CA) (Figure S1). 
For dispersion assays, three culture conditions were utilized and consist of DMEM, 5% 
FBS, and 1% penicillin‐streptomycin, supplemented with either: (a) vehicle (0.05% 
dimethyl sulfoxide [DMSO], Sigma Aldrich), (b) 100 ng/mL BDNF recombinant human 
protein (ThermoFisher, #10908010), or (c) 5 μM ANA‐12 (Selleckchem, #S7745) at 37°C, 
5% CO2. 
2.2 VIABILITY ASSAY 
 
 
Cancer and SC were seeded in 0.01% poly‐L‐ornithine (Sigma Aldrich) and laminin (5 
μg/mL) coated 96‐well black plates at 10 000 cells/well and incubated for 96 hours in each 
of three conditioned media (n = 9‐14). CellTiter‐Glo viability assays (Promega, Fitchburg, 
WI) were conducted per manufacturer's protocol and relative luminescence units (RLU) 
were measured using a GloMax Discover luminometer (Promega, Fitchburg, WI). The 
culture conditions tested did not stimulate proliferation or initiate significant toxicity to 
cancer and SC (P = .32 and P = .27, respectively; Figure S2). 
2.3 WESTERN BLOT 
Western blots were performed to confirm expression of TrkB receptor and BDNF in both 
cancer and Schwann cell‐lines (Figure S3). Protein was isolated using Mem‐PER Plus 
Membrane Protein Extraction Kit (ThermoFisher, 89842, Waltham, MA). Protein 
concentration was measured using the BCA Protein Assay Kit (Pierce, Waltham, MA), 
per manufacturer's instruction. For western blotting, 25 to 100 μg of proteins were loaded 
on a precast gel (MINI‐protean TGX‐Stain‐Free Gel, Bio‐Rad), separated by gel 
electrophoresis, and transferred to a nitrocellulose membrane. Membranes were blocked 
in 2.5% BSA and incubated overnight in primary antibody solution at 4°C and Alexa Fluor 
488 and 647‐conjugated secondary antibodies (1:200, Life Technologies) for 2 hours at 
room temperature. The following primary antibodies were used: BDNF (1:500, Abcam, 
Ab78078, Cambridge, MA), TrkB (1:500, Abcam, Ab187041, Cambridge, MA), beta‐actin 
(1:1000, Abcam, Ab8227, Cambridge, MA), and beta‐tubulin (1:1000, ThermoFisher, 32‐
2600, Waltham, MA). Fluorescent images were obtained using the ImageQuant LAS 4000 
Gel Biomolecular Imager (GE Healthcare Life Sciences). Monochromatic images 
demonstrated confirm expression of TrkB receptor and BDNF in both Schwann and 
cancer cells (Figure S3). 
 
2.4 MIGRATION AND DISPERSION ASSAY 
We created a migration and dispersion assay using 2‐well insert dishes (Ibidi, 81 176, 
Fitchburg, WI), precoated with 0.01% poly‐L‐ornithine (Sigma Aldrich) and laminin (5‐ 10 
μg/mL). Approximately 25 000 cancer cells and SC were plated into each well for 24 hours 
 
 
in their respective culture media at 37°C, 5% CO2 (Figure 2). After cells adhered to the 
dish, Qtracker (Thermo Fisher) was used to fluorescently label the cells per 
manufacturer's protocol. Cancer was labeled green (Qtracker 565, Q25031MP, 
Invitrogen, Eugene, OR) and SC were labeled pink (Qtracker 655, Q25021MP, Invitrogen, 
Eugene, OR). The inserts were removed, and the migration and dispersion assays were 
performed in three types of medias. Time lapse photos were taken daily for four days 
using a fluorescence microscope (Zeiss Axiovert 200 M, Germany). Day 0 photos were 
used to define the gap between cancer cells and SC. Cell migration was measured on 
days 0‐2. Cancer cell dispersion was quantified with images obtained on day 4. This 
assay was replicated 9 to 14 times, depending on condition. 
Figure 2 
 
 
Migration assay. A, Representative images on days 0, 1, and 2 of cancer cells (green) 
and Schwann cells (pink) that have migrated into the gap following treatment with 0.05% 
DMSO (vehicle), 100 ng/mL BDNF, and 5 μM ANA‐12 (TrkB inhibitor). B and C, The 
average number of each cell type were measured within the gap on days 1 and 2. There 
was no significant difference in cancer migration between all three conditions. However, 
there was significantly more SC migration on day 2 in the presence of TrkB inhibitor when 
compared to BDNF (P = .01; Kruskal‐Wallis and Wilcoxin rank sum tests). Bar represents 
 
 
mean. Error bars denote SE mean. * P  < .05. N = 9‐14 replicates per condition [Color 
figure can be viewed at wileyonlinelibrary.com] 
2.5 IMMUNOHISTOCHEMISTRY 
Approximately 10 000 SC per well were plated onto 16‐well chamber slides (Nunc Lab‐
Tek, ThermoFisher, Waltham, MA) for 96 hours in the three conditioned medias. The 
slides were fixed with 4% paraformaldehyde, blocked, and permeabilized with 1% Triton 
X‐100 (Sigma Aldrich), 5% donkey serum (Sigma Alrich), in phosphate buffered saline 
(PBS, Sigma Aldrich). Subsequently, they were incubated with primary antibodies against 
GFAP overnight at 4°C, followed by Alexa Fluor 488 and 633‐conjugated secondary 
antibodies (Life Technologies, A11008, A21070,), and 4′,6‐diamidino‐2‐phenylindole 
(DAPI) nuclear stain. Antifade mounting medium was placed on slides prior to cover‐
slipping. Images were obtained using a confocal microscope (Carl Zeiss LSM 700 Laser 
Scanning Confocal Microscope, Germany). 
2.6 STATISTICAL ANALYSIS 
Statistical analysis was performed with either: (a) analysis of variance test with Tukey‐
Kramer post‐hoc tests for normally distributed data, or (b) two‐sided Kruskal‐Wallis test 
with Wilcoxon rank sum post‐hoc tests for data without normal distribution. Significance 
was set at P  < .05. 
3. RESULTS 
3.1 MIGRATION ASSAY 
Migration was measured by counting the number of cells of each cell type within the gap 
between cancer and SC. The size of the cell free gap was determined on day 0 after the 
well inserts were removed. By day 2, the gaps were completely filled with cells, which 
marked the end point for measuring migration. In all three conditions, there was more 
cancer migration into the gap than SC migration (Figure 2A). There was no difference in 
cancer migration across the three conditions (P = .53; Figure 2B). Although there was no 
significant difference in SC migration on day 1, differences were observed on day 2 (P = 
 
 
.04). On day 2, there was significantly more SC migration in the presence of TrkB inhibitor 
(ANA‐12) when compared to BDNF conditions (P = .01) (Figure 2C). 
3.2 DISPERSION ASSAY 
For the dispersion assay, the average number of cancer cells dispersed by SC were 
measured on day 4. Representative images are shown in Figure 2A. In control and BDNF 
conditions, there was significant mixing of cells, with SC intercalating and encircling 
clusters of cancer cells. In contrast, there appeared to be a very well defined border 
between SC and cancer cells in the presence of TrkB inhibitor, ANA‐12 (Figure 3A). SC‐
associated cancer cell dispersion was quantified by counting the number of cancer cells 
that were completely surrounded by SC. In the presence of TrkB inhibitor, there was 
significantly less cancer cell dispersion, when compared to BDNF and control groups (P 
 < .001 and P  < .001, respectively). There was no significant difference between BDNF 
and control conditions (P = .14; Figure 3B). 
Figure 3 
 
Dispersion assay. A, Representative images on day 4 at 6× magnification of cancer cells 
(green) and Schwann cells (pink) after treatment with 0.05% DMSO (control), 100 ng/mL 
BDNF, and 5 μM ANA‐12 (TrkB inhibitor). There was significantly more intercalation and 
mixing of cancer cells and Schwann cells at the border in control (DMSO) and BDNF 
conditions, whereas there is a well‐defined border between cell types with TrkB inhibition 
(ANA‐12). B, Cancer cell dispersion was measured by the number of cancer cells that 
 
 
were completely surrounded by Schwann cells. There was significantly less cancer cell 
dispersion with the addition of a TrkB inhibitor (ANA‐12), when compared to both control 
(DMSO) and BDNF conditions (P  < .001 and P  < .001, respectively; Kruskal‐Wallis and 
Wilcoxin rank sum tests). There was no significant difference between BDNF and control 
conditions. Bar represents mean. Error bars denote SE mean. N = 11‐14 replicates per 
condition. NS, not significant. *** P  < .01 [Color figure can be viewed at 
wileyonlinelibrary.com] 
3.3 IMMUNOFLUORESCENCE AND DEDIFFERENTIATION 
To determine whether SC have the propensity to dedifferentiate under certain conditions, 
immunofluorescence was performed on SC exposed to either control, BDNF, or TrkB 
inhibition (ANA‐12) conditions. GFAP was used as a marker of a dedifferentiated and 
motile state. In control conditions, SC expressed an intermediate degree of GFAP. In the 
presence of BDNF, there was minimal GFAP staining, suggesting that BDNF may 
promote SC conversion into a more mature state. In contrast, when exposed to a TrkB 
inhibitor, there was intense GFAP expression, which suggests a more dedifferentiated 
and motile form (Figure 4). 
Figure 4 
 
Immunofluorescence. To evaluate the effect of BDNF and TrkB inhibition on Schwann 
cell dedifferentiation, we cultured Schwann cells for 96 hours in 0.05% DMSO (control), 
100 ng/mL BDNF, and 5 μM ANA‐12 (TrkB inhibitor). Immunofluorescence for GFAP 
(green), a marker of dedifferentiation, was performed. Images were taken at 20× 
magnification. Nuclei were labeled with DAPI (blue). In control conditions, there is 
intermediate staining of GFAP. In the presence of BDNF, there is minimal GFAP 
 
 
expression, signifying a more quiescent state. In the presence of TrkB inhibitor (ANA‐12), 
there is intense GFAP, signifying a more dedifferentiated state [Color figure can be 
viewed at wileyonlinelibrary.com] 
4. DISCUSSION 
Investigations into PNI can be dated as far back as 1963; however, the mechanisms of 
action remain clouded.19 While PNI in HNSCC is usually asymptomatic, advanced stage 
disease can be associated with significant morbidity as the cranial nerves become more 
grossly involved in the disease. Even microscopic PNI can have a negative impact on 
patient quality of life, as it is an indication to initiate adjuvant radiotherapy for head and 
neck cancer. Even so, prognosis is worse with PNI with regards to locoregional control.20 
Understanding the interactions between cancer cells and the nerve microenvironment 
can lead to development of new therapeutic interventions for patients with PNI. Based on 
recent studies, SC and neurotrophic factors are important targets to explore and could 
have substantial implications for risk stratification and guidance of treatment. Recent 
studies have shown that SC properties that are used in nerve repair may also be activated 
in response to cancer. Dedifferentiated SC re‐express proteins such as GFAP and NCAM 
during nerve repair. Deborde et al9 showed how SC that express NCAM can migrate 
toward pancreatic cancer cells, intercalate between cancer cell clusters, and direct cancer 
cell migration toward nerves.9 Our study shows similar findings in our in vitro model with 
SC dispersing cancer cells by extending their processes to intercalate and surround 
cancer cell clusters. 
Demir et al 10 showed through a series of three‐dimensional in vitro experiments that 
both human and rat SC exhibit early and targeted migration toward human pancreatic 
cancer cells well before the onset of pancreatic cancer cell migration toward neurons. 
This highly specific migration of GFAP‐positive SC toward cancer cells was also seen in 
the presence of human colon cancer cells, but was not seen in response to benign human 
pancreatic and colon epithelial cells or benign glioblastoma cells. These findings 
suggested that SC are activated in response to cancer cells, and then migrate toward 
cancer before the onset of cancer migration toward nerves. Interestingly, when SC were 
pretreated with an inhibitor of TrkA, the high affinity receptor for NGF, both of which are 
 
 
highly expressed in pancreatic cancer, they found a decrease in Schwann cell migration 
toward pancreatic cancer.10 
Evidence has shown that neurotrophic receptor B (TrkB), a receptor tyrosine kinase, is 
an important regulator of oncogenesis and tumor progression in nerve tissue. Multiple 
studies have eluded to the involvement of TrkB in increasing migratory and invasion 
capacities of neurogenic tumor cell lines,21 promoting cancer cell survival,22 inhibiting 
chemotherapy‐induced apoptosis of cancer,23 and developing metastasis in mouse 
models.24, 25 These findings suggest that TrkB and its ligand BDNF are critical 
components for cancer growth and progression, making it an avenue to study 
interventions for PNI. 
In our study, we chose to evaluate the effect of BDNF and TrkB due to increasing number 
of reports showing elevated expression of these molecules and receptors in head and 
neck cancer.17, 26, 27 Our work is in line with recent studies that SC may play a role in 
promoting PNI. We demonstrate that when human tongue cancer and SC are grown in 
coculture, there is significant intercalation and mixing of both cell types (Figure 3). We 
can modulate these interactions by exogenous administration of BDNF or TrkB inhibitor. 
While there were high levels of cellular intermixing with BDNF treatment, TrkB inhibition 
with ANA‐12 resulted in a well‐defined border between cancer cells and SC. These 
findings suggest that TrkB inhibition may be altering the microenvironment in such a way 
that it is preventing the intercalation of SC and forming a barrier to cancer cell dispersion. 
Further investigations are warranted. 
Our investigation also demonstrates that human SC and cancer cells express both BDNF 
and TrkB and exogenous administration of recombinant BDNF and TrkB inhibitor can 
modulate SC differentiation (Figure 4). When SC are treated with BDNF, they do not 
express GFAP, suggesting a more quiescent and myelinating state. When SC are 
exposed to TrkB inhibitor, they express intense GFAP staining, suggesting the cells have 
transformed into a more dedifferentiated and motile state. The association between SC 
dedifferentiation with TrkB inhibition and the prevention of cancer cell dispersion is not 
entirely clear; however, demonstrates a phenomenon that may be protective against 
cancer cell invasion. 
 
 
Although advantageous for studying mechanisms of action between individual cells types, 
the main limitation of two‐dimensional in vitro models is that it does not replicate the three‐
dimensional microenvironment that is better investigated using in vivo or even three‐
dimensional in vitro models. In addition, while we are studying potential mechanisms of 
PNI, we chose not to include neurons in this pilot study to avoid confounding factors at 
this early level of investigation. While HNSCC is known to invade nerves, there are other 
cell lines in the head and neck that are more prone to PNI, such as adenoid cystic 
carcinoma. Studying these cells lines may give more clues toward mechanisms of PNI; 
however, there is controversy whether available cell lines are representative of adenoid 
cystic carcinoma and therefore they were not utilized. Furthermore, there are many 
factors that can potentially influence PNI, including other neutrophins, chemokines, and 
extracellular matrix components. This study focuses on the impact of the BDNF‐TrkB axis 
on SC migration and dispersion of HNSCC. Future directions should include multiple 
cancer and SC lines and in vitro models of PNI, including use of neuronal and dorsal root 
ganglion cultures. Moreover, TrkB inhibition in animal models of PNI should be explored. 
5. CONCLUSION 
In addition to HNSCC, PNI is found in a number of different cancers, such as pancreas, 
colon, rectum, gastric, prostate, and biliary tract. Understanding the role of SC and 
neurotrophic factors in the pathophysiology of PNI may have important implications for 
therapeutic intervention. The need to identify the exact mechanisms of PNI is evident and 
further studies are warranted. 
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